X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AKANTIOR® (polihexanide) is an investigational anti-amoebic polymer that has been granted Orphan Drug Designation by both the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA") for AK.
Lead Product(s): Polyhexanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Avanzanite Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2023
Details:
87% of patients receiving AKANTIOR® in the Phase 3 Trial were medically cured within a median duration of 4 months compared to 55% with the treatment protocols used in real-world clinical practice today.
Lead Product(s): Polyhexanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into back of eye,is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce recurrence of disease.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Alimera Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Lead Product(s): Polyhexanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Durbin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world. Polihexanide, a New Chemical Entity (NCE), is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Lead Product(s): Polyhexanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
ProGIFT is a multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial comparing different concentrations of Pro-ocular (1% and 0.5%) versus placebo.
Lead Product(s): Progesterone
Therapeutic Area: Ophthalmology Product Name: Pro-ocular
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
SIFI is conducting a multi-center randomized, double-masked, and active-controlled Phase III trial designed to evaluate the efficacy, safety, and local tolerability of polihexanide 0.08% compared to a combination of polihexanide 0.02% and 0.1% propamidine.
Lead Product(s): Polyhexanide
Therapeutic Area: Ophthalmology Product Name: PH043
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
